Gilead Sciences, Inc. (GILD)

Acerca de Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Al 3 de noviembre de 2026, la acción de Gilead Sciences, Inc. (GILD) avanzó ligeramente a $170.82, un alza de 0.29% (+$0.49) frente al cierre anterior. En la sesión, las acciones han operado entre $168.75 y $171.47. Eso ubica a GILD cerca del máximo de su rango de 52 semanas, de $116.88 a $175.65. Gilead Sciences, Inc. opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $211.27 mil millones, con cerca de 764.2 mil acciones negociadas.

Últimas noticias de GILD

• BioNTech Announces Third Quarter 2026 Financial Results and Corporate UpdateYahoo Finance· 3 nov, 6:45 a.m. ETL
• Gilead (GILD) Stock Fair Value Edges Higher After Analyst Target IncreasesYahoo Finance· 2 nov, 1:07 p.m. ET
• Former Gilead Head of U.S. Medical Affairs Dean Hakanson, MD, Joins GOA Therapeutics as Chief Medical OfficerYahoo Finance· 2 nov, 10:00 a.m. ET
• Should You Buy The Dip In Alnylam Stock?trefis.com· 2 nov, 9:39 a.m. ET
• Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV GlasgowYahoo Finance· 2 nov, 8:30 a.m. ET
• Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week?stocktwits.com· 1 nov, 9:48 p.m. ET
• 1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in Novemberfool.com· 1 nov, 4:02 p.m. ET
• GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loomYahoo Finance· 31 oct, 3:07 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de GILD en un solo lugar? Crea una cuenta gratis →

• $SLS $GILD Just the Secondary asset is already worth 3x the current short rigged mcap. List of FDA Approved drugs based on Ph1/2 pivotal trial results - same stage as SLS009 will report this month or next. Top Line PIVOTAL Trial RESULTS for AML-MR Front Line Patients - This Qu…

  @55X_ROI_Q1_2026· 3 nov, 9:23 a.m. ET

• $SLS $GILD Just the Secondary asset is already worth 3x the current short rigged mcap. List of FDA Approved drugs based on Ph1/2 pivotal trial results - same stage as SLS009 will report this month or next. Top Line PIVOTAL Trial RESULTS for AML-MR Front Line Patients - This Qu…

  @55X_ROI_Q1_2026· 3 nov, 2:40 a.m. ET

• $SLS $GILD Oddly Coincidental the 80th Event was Announced on October 28 - but - but for the First Time ever, the co did not Time Stamp the actual date the Event Occurred --- in all other Event Milestone PR's the Date of the Event itself was included in the PR. Not this ti…

  @55X_ROI_Q1_2026· 2 nov, 11:10 p.m. ET· Alcista

• $SLS $GILD Why does SLS for the first time in Corp History have A MASSIVE BOOTH at the ASH Exhibition Hall? Late Breaker Abstract DEADLINE was OCT 28... The SAME DAY SLS announced the 80th - but no definition on WHEN the 80th occurred. -- Did they Submit GPS TOP LINE DATA ? wh…

  @55X_ROI_Q1_2026· 2 nov, 3:48 p.m. ET

• $SLS $GILD Why does SLS for the first time in Corp History have A MASSIVE BOOTH at the ASH Exhibition Hall? Late Breaker Abstract DEADLINE was OCT 28... -- Did they Submit GPS TOP LINE DATA ? which they easily could Pull, EVENT Rates by ARM for instance - is Known Immediately …

  @55X_ROI_Q1_2026· 2 nov, 3:33 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →